ARMP news

Armata Pharmaceuticals received an additional $3.7 million in non-dilutive support from the U.S. Department of War to advance the Phase 3 development of its phage therapy candidate AP-SA02.

Armata Pharmaceuticals received a Breakthrough Therapy designation from the FDA for AP-SA02 based on Phase 2 clinical data showing potential for substantial improvement over existing treatments for complicated S. aureus bacteremia. This adds to the company's existing regulatory designations.

Armata submitted a Phase 3 protocol and FDA responses to advance its staphylococcus aureus therapy toward a pivotal 2026 trial, supported by DoD funding.

Armata Pharmaceuticals received FDA agreement on the Initial Pediatric Study Plan (iPSP) for AP-SA02 to treat resistant staph infections in children. This regulatory milestone advances the company toward a Biologics License Application for pediatric patients.

Armata Pharmaceuticals announced receiving $2.5 million in non-dilutive funding from the Department of Defense to support clinical development of AP-SA02 for antibiotic-resistant infections. The award enhances the company's cash position and bolsters the path to regulatory approval for a critical un…